New hope for bladder cancer! Pfizer (PFE.US) immunotherapy's key phase 3 trial has reached its primary endpoint.

Pfizer (PFE.US) announced today that its PD-1 targeting monoclonal antibody sasanlimab has reached the primary endpoint in the pivotal Phase 3 CREST trial.

Zhitong Finance15:16

Pfizer Options Spot-On: On January 10th, 114.74K Contracts Were Traded, With 3.27 Million Open Interest

On January 10th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 114.74K options for the day, of which put options accounted for 39.78% of the total transactions, and

Futu News05:30

BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

Benzinga03:54

Express News | FDA: Hospira's Marcaine, Injection, 250 Mg/50 Ml (5 Mg/Ml); Multiple Dose Glass Fliptop Vial Discontinued - Website

Breakings03:49

Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

MT Newswires03:37

Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure

BenzingaJan 10 21:35